New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background
Authors
Keywords
Non-small cell lung cancer (NSCLC), Adenocarcinoma, Targeted therapies, Signal transduction pathway, Tyrosine kinase inhibitors, Monoclonal antibodies, EGFR mutation, KRAS, EML-4 ALK, VEGFR
Journal
PATHOLOGY & ONCOLOGY RESEARCH
Volume 20, Issue 1, Pages 11-25
Publisher
Springer Nature
Online
2013-12-04
DOI
10.1007/s12253-013-9719-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRASMutation: Should We Test for It, and Does It Matter?
- (2013) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- New Targetable Oncogenes in Non–Small-Cell Lung Cancer
- (2013) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents
- (2013) K. W. Robinson et al. ONCOLOGIST
- KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy
- (2012) Ji-lin Guan et al. ANNALS OF SURGICAL ONCOLOGY
- Antiangiogenic agents in the management of non-small cell lung cancer
- (2012) Charu Aggarwal et al. CANCER BIOLOGY & THERAPY
- Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors
- (2012) Song Dong et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Immune alterations and emerging immunotherapeutic approaches in lung cancer
- (2012) Constantin A Dasanu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
- (2012) Luis Paz-Ares et al. LANCET ONCOLOGY
- A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
- (2011) G. R. Blumenschein Jr et al. ANNALS OF ONCOLOGY
- Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
- (2011) C.P. Belani et al. CANCER TREATMENT REVIEWS
- New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
- (2011) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Crizotinib: an anaplastic lymphoma kinase inhibitor
- (2011) Shirish M Gadgeel et al. Future Oncology
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- NSCLC Drug Targets Acquire New Visibility
- (2011) M. J. Friedrich JNCI-Journal of the National Cancer Institute
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- Lung cancer in never smokers: Change of a mindset in the molecular era
- (2011) Young Joo Lee et al. LUNG CANCER
- Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities
- (2011) Elizabeth M. Gaughan et al. Therapeutic Advances in Medical Oncology
- Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy
- (2010) E. Ardini et al. CANCER LETTERS
- Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
- (2010) Donatella Malanga et al. CELL CYCLE
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- (2010) M. Mino-Kenudson et al. CLINICAL CANCER RESEARCH
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
- (2010) J. S. W. Lind et al. CLINICAL CANCER RESEARCH
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
- (2010) J. Matthew Reinersman et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
- (2010) Lucio Crinò et al. LANCET ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
- (2009) S Novello et al. BRITISH JOURNAL OF CANCER
- Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
- (2009) Quincy Siu-Chung Chu EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
- (2009) Joan H. Schiller et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
- (2009) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- (2009) Christopher G. Azzoli et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
- (2009) N. A. Pennell et al. ONCOLOGIST
- Cell Culture Modeling of Genotype-Directed Sensitivity to Selective Kinase Inhibitors: Targeting the Anaplastic Lymphoma Kinase (ALK)
- (2009) Jeff Settleman SEMINARS IN ONCOLOGY
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
- (2008) U. McDermott et al. CANCER RESEARCH
- Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma
- (2008) J. L. Marks et al. CANCER RESEARCH
- Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials
- (2008) JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
- (2008) R. S. Herbst et al. ONCOLOGIST
- The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer
- (2008) C. Gridelli et al. ONCOLOGIST
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now